First-line trials

These trials are for patients that have never had Gleevec before (although some may allow previous adjuvant Gleevec, check the trial details). The intent of these trials is to try to improve on the initial response to therapy. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

6 trials found

Imatinib

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT05009927 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Institut Paoli-Calmette Marseille Bouches du Rhone France
Instituit Curie Paris France
CHU de Reimes - Hôpital Pontchaillou Reims Marne France
St. Herblain Saint-Herblain Loire Atlantique France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Institut de Cancérologie de Lorraine Vandoeuvre-les-Nancy Meurthe et Moselle France
Institut Gustave Roussy Villejuif Val de Narne France
Hôpital Jean Minjoz Besancon Doubs France
Centre Eugene Marquis Rennes Isle-et-Vilane France
Institut de Cancérologie Neuwirth Saint Priest en Jarez Loire France
CHU Dupuytren Limoges France


Imatinib

Imatinib TDM (Therapeutic Drug Monitoring) in GIST
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT05493215 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
University of Kentucky/Markey Cancer Center Lexington KY USA


KQB198 + Imatinib

KQB198 in Combination With Imatinib in Participants With Advanced/​Metastatic GIST in 1st Line Setting
Phase: 
2 Drug Category: RAS Pathway inhibitor
NCT#:
NCT07406633 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Fred Hutchinson Cancer Research Center Seattle WA USA
MD Anderson Cancer Center Houston TX USA
USC-Norris Cancer Center Los Angeles CA USA


Pemigatinib

PEMIGIST: Phase 2 Study of Pemigatinib (INCB054828) in the Treatment of Patients With Advanced SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Phase: 
2 Drug Category: SDH-directed
NCT#:
NCT07434843 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA


deepGeneAI-001 + Sintilimab

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment (PCV-GSTT)
Phase: 
1 Drug Category: Personalized vaccine + PD-1 inhibitor
NCT#:
NCT07067385 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Ruijin Hospital Shanghai China


Surgery

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Phase: 
Drug Category: SDH-directed
NCT#:
NCT04557969 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
National Cancer Institute Bethesda MD USA


6 trials found